Cases in the management of metastatic colorectal cancer: regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a KRAS mutation

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalClinical advances in hematology & oncology : H&O
Issue number8
StatePublished - Aug 1 2021

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this